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The C3-V4 region is a major target of autologous neutralizing antibodies in HIV-1 subtype C infection. We
previously identified a Center for AIDS Program of Research in South Africa (CAPRISA) participant, CAP88,
who developed a potent neutralizing-antibody response within 3 months of infection that targeted an epitope
in the C3 region of the HIV-1 envelope (P. L. Moore et al., PLoS Pathog. 5:e1000598, 2009). Here we showed
that these type-specific antibodies could be adsorbed using recombinant gp120 from the transmitted/founder
virus from CAP88 but not by gp120 made from other isolates. Furthermore, this activity could be depleted
using a chimeric gp120 protein that contained only the C3 region from the CAP88 viral envelope engrafted onto
the unrelated CAP63 viral envelope (called 63-88C3). On the basis of this, a differential sorting of memory B
cells was performed using gp120s made from 63-88C3 and CAP63 labeled with different fluorochromes as
positive and negative probes, respectively. This strategy resulted in the isolation of a highly specific monoclonal
antibody (MAb), called CAP88-CH06, that neutralized the CAP88 transmitted/founder virus and viruses from
acute infection but was unable to neutralize CAP88 viruses isolated at 6 and 12 months postinfection. The
latter viruses contained 2 amino acid changes in the alpha-2 helix of C3 that mediated escape from this MAb.
One of these changes involved the introduction of an N-linked glycan at position 339 that occluded the epitope,
while the other mutation (either E343K or E350K) was a charge change. Our data validate the use of
differential sorting to isolate a MAb targeting a specific epitope in the envelope glycoprotein and provided
insights into the mechanisms of autologous neutralization escape.
HIV-1-infected individuals develop antibodies within a few
months of infection that are capable of neutralizing the infect-
ing virus (9, 13, 23, 33). These antibodies are often highly
potent and appear to be effective in vivo since the virus pop-
ulation is rapidly replaced by neutralization-resistant variants
(21, 23, 33). However, these antibodies are generally type spe-
cific and have little to no cross-neutralizing activity, suggesting
that they target highly variable regions of the envelope glyco-
protein. Indeed, using a series of chimeric viruses, we found
that antibodies directed against the V1V2, V4, V5, and, in
particular, C3 and C3-V4 regions mediated the early autolo-
gous neutralization response in HIV-1 subtype C infection (19,
21). The C3 region is located in the outer domain of gp120,
expanding from the C-terminal stem of the V3 loop to the V4
region, including the alpha-2 helix and the CD4 binding loop
(12). The length of the C3 region is approximately 54 amino
acids (HxB2 numbering, amino acids 332 to 384) and contains
at least 3 N-linked glycans (12). The alpha-2 helix, which spans
18 amino acids from positions 335 to 352, has a very conserved
amphipathic structure among subtype C strains, with most
variation occurring at the solvent-exposed hydrophilic face (7).
The higher diversity in the alpha-2 helix of subtype C viruses
compared to subtype B viruses (6) supports the experimental
findings that this region is commonly targeted by autologous
neutralizing antibodies (21, 24).
We have previously identified a subtype C-infected individ-
ual from the Center for AIDS Program of Research in South
Africa (CAPRISA) cohort (CAP88) whose initial autologous
neutralizing-antibody response targeted the C3 region of
gp120 (19). These antibodies first appeared at 11 weeks of
infection and peaked at 26 weeks. Escape was mediated by 2
amino acid changes in the alpha-2 helix of C3, which were first
detected at 15 weeks postinfection, becoming the major pop-
ulation after 20 weeks of infection. One of the mutations in-
troduced an N-linked glycosylation site at position 339, and the
other involved charge changes from a negatively charged glu-
tamic acid (E) to a positively charged lysine (K) at either
position 343 or 350. While the plasma antibodies from CAP88
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at these early stages of infection were essentially monospecific,
the isolation of a monoclonal antibody (MAb) was desirable, as
this would conclusively prove that potent autologous neutral-
ization was effected by a single antibody specificity. Further-
more, a MAb would enable characterization of the epitope and
the mechanism of escape and also allow the analysis of antigen-
specific antibody genes mediating this early antibody response.
Recent methodological advances in the ability to identify
neutralizing-antibody specificities have facilitated the design of
suitable antigens with which to isolate antigen-specific memory
B cells. The combination of antigen-specific memory-B-cell
sorting and single-cell amplification of antibody-variable re-
gions has resulted in the isolation of a new generation of
HIV-1-neutralizing MAbs (25, 26). Using a peptide tetramer
to sort antigen-specific memory B cells, we recently isolated a
cross-neutralizing MAb, CAP206-CH12, that recognized a
novel epitope in the membrane proximal external region
(MPER) of gp41 (22). In another study, structural information
was used to generate probes to isolate B cells expressing anti-
bodies to the conserved CD4 binding site, which resulted in the
isolation of the very broad and potent MAb VRC01 (34). Here
we describe the isolation of an autologous neutralizing anti-
body from participant CAP88 by a differential antigen-specific
memory-B-cell sorting strategy using a chimeric gp120 where
the C3 region of the autologous virus was grafted into an
unrelated gp120. Furthermore, characterization of the neutral-
ization and binding properties of this antibody provided insight
into the escape pathways in this individual.
MATERIALS AND METHODS
Human samples and envelope clones. The stored plasma and peripheral blood
mononuclear cell (PBMC) samples analyzed in this study were obtained from
participant CAP88 from the CAPRISA 002 Acute Infection Cohort. This study
was reviewed and approved by the research ethics committees of the University
of KwaZulu Natal and the University of the Witwatersrand in South Africa. The
envelope genes were either previously cloned in our laboratory (9, 21) or ob-
tained from the NIH AIDS Research and Reference Reagent Program or the
Programme EVA Centre for AIDS Reagents, NIBSC, United Kingdom.
Cell lines. Cells of the JC53bl-13 cell line, also known as TZM-bl cells,
engineered by J. Kappes and X. Wu, were obtained from the NIH AIDS Re-
search and Reference Reagent Program. Human embryonic kidney 293T cells
were obtained from George Shaw (University of Alabama, Birmingham, AL),
and N-acetylglucosamine transferase I-deficient 293S cells were obtained from
James Binley (Torrey-Pines Institute). Both cell lines were cultured in Dulbecco
modified Eagle medium (DMEM; Gibco, Invitrogen, Carlsbad, CA) containing
10% heat-inactivated fetal bovine serum (FBS) and 50 g/ml gentamicin (Sigma-
Aldrich, St. Louis, MO). Cell monolayers were disrupted at confluence by treat-
ment with 0.25% trypsin in 1 mM EDTA.
Generation of chimeras and mutant envelopes. Chimeric envelopes were cre-
ated using an overlapping PCR strategy with the inserts and flanking regions
amplified in separate reactions. After linkage, the 3-kb chimeric PCR fragments,
generated using EnvAdir and EnvM primers (5), were cloned into plasmid
pcDNA3.1 (directional; Invitrogen) and screened for function as previously
described (8). Chimerism was confirmed by sequence analysis. Site-directed
mutagenesis was performed using a Stratagene QuikChange II kit (La Jolla, CA).
Production of pseudoviruses. Envelope-pseudotyped viruses were obtained by
cotransfecting the envelope plasmids with pSG3Env (33) using FuGene 6
transfection reagent (Roche, Basel, Switzerland) as previously described (9). In
some cases pseudoviruses were generated either in 293T cells treated with the
glycosidase inhibitor kifunensine at 23 g/ml (100 M) before transfection or in
GnTI-deficient 293S cells.
Production of infectious envelope clones. Replicating viruses were prepared
from specific envelope clones as described elsewhere (16). The vector
pHIVenvBstEIInef-hisD was a gift from D. R. Kuritzkes. Briefly, linearized
vector pHIVenvBstEIInef-hisD and full gp160 envelope PCR products were
cotransfected into 293T cells with FuGene 6. Supernatants were harvested on
day 4 and were used to infect activated CD8-depleted PBMCs via spinoculation.
Viruses were harvested from the culture supernatants every second day until day
10 and tested for infectivity in JC53bl-13 cells. The 50% tissue culture infective
dose in PBMCs was determined for each virus preparation as described else-
where (18).
gp120 production and isolation. Recombinant gp120 proteins were produced
in 293T cells by transfection using codon-optimized gp120 genes cloned in the
expression vector in plasmid pcDNA3.1 (Invitrogen). gp120 was isolated using
Galanthus nivalis lectin agarose matrix (Sigma) and eluted with 1 M methyl--
D-mannopyranoside (Sigma). Remaining protein contaminants were eliminated
through ion-exchange chromatography using FastFlow Q-Sepharose (GE
Healthcare Life Science, Piscataway, NJ), equilibrated in phosphate-buffered
saline (PBS), and reconstituted in 2 M NaCl-PBS. The purified gp120s were
collected in the flowthrough, washed in PBS, and concentrated to 5 mg/ml. The
purities of the final gp120 preparations were tested by running 10 g of protein
in an SDS-polyacrylamide gel. Protein preparations with purity higher than 99%
were used in subsequent experiments.
Adsorption of gp120-binding antibodies in plasma. Adsorption of anti-gp120
antibodies was done as previously described (14), using gp120 covalently coupled
to tosyl-activated magnetic beads. Anti-gp120 activity was measured by enzyme-
linked immunosorbent assay (ELISA) as described elsewhere (14).
Neutralization assays. Neutralization was measured as a reduction in lucifer-
ase gene expression after a single-round infection of TZM-bl cells with envelope-
pseudotyped viruses (18). Titers were calculated as the inhibitor concentration
(IC50) or reciprocal plasma/serum dilution (ID50) causing a 50% reduction of
relative light units (RLU) with respect to the virus control wells (untreated
virus). Neutralizing activity was also measured as a reduction in PBMC infection
by measuring p24 Gag antigen synthesis as described previously (3).
Staining and sorting B-cell populations. For antigen-specific memory-B-cell
sorting, CAP63 gp120 and a chimeric protein containing the C3 region of CAP88
in the CAP63 backbone (63-88C3) were labeled with Pacific Blue and Alexa
Fluor 647, respectively, using fluorochrome labeling kits (Invitrogen, Carlsbad,
CA). Thawed PBMCs were stained using a viability marker (Aqua vital dye;
Invitrogen, Carlsbad, CA) and a combination of the following antibodies: CD3
phycoerythrin (PE)-Cy5, CD14 PE-Cy5, CD16 PE-Cy5, CD235a PE-Cy5, CD19
allophycocyanin (APC)-Cy7, CD27 PE-Cy7, CD38 APC-Cy5.5, anti- immuno-
globulin M (anti-IgM) fluorescein isothiocyanate (FITC), and anti-IgD PE (BD
Biosciences, Mountain View, CA, and Invitrogen, Carlsbad, CA). The titers of all
antibodies were determined and used at optimal concentrations for flow cytom-
etry. During the sort, forward- versus side-scatter gating was used to select for
lymphocytes, geometric gates were used to eliminate doublet events, and viability
dye gating was used to select for viable cells. Memory B cells were gated as
CD3, CD14, CD16, CD235a, CD19, and IgD negative (IgD). gp120-
stained B cells were sorted as single cells into wells of a 96-well plate,
selecting those cells that were labeled by the 63-88C3 gp120 but not by the
CAP63 gp120. Cells were stored in room temperature reaction buffer at
80°C until use. Flow cytometric data were acquired on a BD Aria2 fluo-
rescence-activate cell sorter (FACS), and the data were analyzed using
FlowJo software (Tree Star, Ashland, OR).
Isolation of Ig variable gene transcripts. The genes encoding Ig variable
region gene segments of heavy chain (VH) and light chain (VL) were amplified
by reverse transcription-PCR using a modification of the method described by
Tiller and coworkers (29). Briefly, RNA from single B cells sorted in 96-well
plates were reverse transcribed using Superscript III in the presence of primers
specific for human IgG, IgM, IgD, IgA1, IgA2, kappa (K), and lambda (L)
constant gene regions (15). The VH, VK, and VL genes were then amplified from
the transcribed cDNA separately by nested PCR, as described elsewhere, and
analyzed on 1.2% agarose gels (15). The second-round PCR includes tag se-
quences at the 5 end of each primer pair which permit assembling of the VH and
VL genes into functional linear Ig gene expression cassettes (see below). PCR
products were purified and sequenced. The variable gene segments, isotype, and
potential functionality of the immunoglobulin were determined using the SoDA
program (31).
Expression of recombinant antibodies from linear expression cassettes. Three
linear Ig expression cassettes, each containing the cytomegalovirus promoter and
human Ig leader as one fragment, were used for small-scale expression and
specificity analysis (15). Fragments for the heavy and light chains comprised
either the IgG1 constant region, Ig kappa constant region, or Ig lambda constant
region attached to poly(A) signal sequences. These two fragments plus either the
VH, VK, or VL gene amplified from single B cells as described above were
assembled by overlapping PCR. PCR products containing linear full-length im-
munoglobulin heavy- and light-chain genes were purified, and the paired Ig
heavy- and light-chain products were cotransfected into 293T cells grown in













6-well plates using Effectene transfection reagent (Qiagen, Valencia, CA). Cul-
tures were fed 6 to 12 h later with 2 ml fresh medium containing 2% fetal calf
serum (FCS) and incubated for 72 h at 37°C in a 5% CO2 incubator. Thereafter,
culture supernatants were harvested for antibody characterization.
Production of purified recombinant MAbs. The selected immunoglobulin VH
and VL genes from CAP88-CH06 were cloned into human Ig() and Ig()
expression vectors in pcDNA3.3 (15). Clones with inserts of the correct size were
sequenced to confirm identity with the original PCR product. For production of
purified antibodies of CAP88-CH06 by batch transient transfections, 293T cells
in 10 to 20 T-175 flasks or a Hyperflask (Corning) grown to 80 to 90% confluence
in DMEM supplemented with 10% FCS were cotransfected with plasmids ex-
pressing HIV-1-specific Ig heavy- and light-chain genes using polyethylenimine.
Recombinant antibodies were purified using protein A-agarose columns
(Thermo, Rockford, IL).
Antibody binding assay. Supernatants from the small-scale transfections were
tested for the amount of IgG present by ELISA and for binding to HIV antigens
by ELISA using standard techniques (1) and Luminex and using a standardized
custom assay (30). Antibodies were tested for reactivity with a panel of HIV-1
Env and other HIV-1 proteins. Samples were serially diluted for assay, and data
were analyzed using 5-parameter curve fitting; endpoint titers were calculated to
be 3-fold above assay background. ELISA testing for antigens was considered
positive if the optical density reading was above 0.13 unit. Affinity of recombinant
MAbs was determined using a 4-parameter curve fit of ELISA titer data.
Luminex assays were considered positive if the value obtained after the value for
the blank bead was subtracted was greater than 20 units and greater than 10
divided by the IgG concentration in % g/ml. Transiently expressed MAbs with
low IgG concentrations were retransfected and reassayed. In cases where mul-
tiple tests of the same antibody were available, the final data set contained data
from the assay with the highest concentration of MAb.
MAb binding to pseudovirus gp120. Pseudovirus supernatants were lysed in
1% Triton X-100 for 1 h. The gp120 molecules in the lysate were captured onto
a solid phase via adsorbed antibody D7324 (Aalto Bio Reagents, Dublin, Ire-
land). MAbs were bound to gp120 in 5% milk–0.05% Tween 20 in PBS. Bound
antibodies were detected using a total anti-human immunoglobulin biotinylated
at 1:3,000 (KPL, Gaithersburg, MD) and antibiotin antibody-horseradish perox-
idase conjugated at 1:1,000 (Calbiochem, Merck, Darmstadt, Germany). The
ELISA was developed with tetramethylbenzidine substrate (Thermo Fisher Sci-
entific, Rockford, IL) and stopped with 1 M H2SO4. Plates were read at 450 nm
on a microplate reader (Molecular Devices, Sunnyvale, CA).
RESULTS
The anti-C3 neutralizing activity can be depleted by mono-
meric gp120. In a previous study we demonstrated that CAP88,
an HIV-1 subtype C-infected woman, developed potent autol-
ogous neutralizing antibodies first detected at 11 weeks of
infection (21). The targets of these early antibodies were
mapped by making chimeras between the CAP88 virus and an
unrelated heterologous CAP63 virus that was insensitive to
CAP88 serum antibodies. Transfer of the C3 region from the
early virus of CAP88 (envelope clone 88.2mo.B5 isolated 2
months postinfection) into a CAP63 backbone resulted in a
virus (clone 63-88C3) that was as sensitive to the earliest au-
tologous neutralizing response as the CAP88 parental virus,
with titers peaking at 26 weeks (Fig. 1A, gray shading) (21).
This indicated that the targets of the earliest autologous re-
sponse were entirely within C3. As the virus escaped these
anti-C3 antibodies, a new response targeting the V1V2 loop
appeared at 26 weeks, becoming dominant at 54 weeks postin-
fection, as demonstrated by the neutralization of the V1V2
chimera (63-88V1V2) (Fig. 1A, striped shading). Analysis of
the escape mutations to the first response mapped the epitope
in C3 to the alpha-2 helix in the outer domain of gp120 (21).
We hypothesized that this epitope in C3 might be apparent
on monomeric gp120. To prove this, we cloned, expressed, and
purified gp120 from the 88.2mo.B5 virus and used this in ad-
sorption/depletion studies. Plasma samples collected at 26 and
54 weeks postinfection were adsorbed with CAP88 and CAP63
gp120-coated beads. Blank beads were used as negative con-
trols. Adsorbed plasma samples were tested for neutralization
against the sensitive autologous virus 88.2mo.B5 (Fig. 1B and
D) and for binding to CAP88 and CAP63 gp120 (Fig. 1C and
E). CAP88 gp120-coated beads completely adsorbed the au-
tologous neutralizing activity from plasma collected at 26
weeks postinfection (Fig. 1B), and this corresponded with al-
most total depletion of CAP88 gp120-binding antibodies (Fig.
1C). This suggested that the epitope targeted by the first au-
tologous antibody response was wholly presented on mono-
meric gp120. However, adsorption of the neutralizing antibod-
ies in plasma collected at 54 weeks postinfection was less
efficient (Fig. 1D), despite the fact that most antibodies bind-
ing to monomeric CAP88 gp120 were removed (Fig. 1E). This
might be due to the fact that the C3 antibody had started to
wane and was being replaced by antibodies targeting an
epitope in V1V2 (Fig. 1A) (21) that was presumably not ad-
sorbed by monomeric gp120. A chimeric 63-88C3 gp120 was
produced to specifically target the anti-C3 antibodies in CAP88
plasma. This protein efficiently depleted antibodies binding to
the 63-88C3 chimeric and CAP63 gp120 proteins in the plasma
collected at 26 weeks (Fig. 1C), which resulted in a 96% re-
duction of neutralizing activity against the 88.2mo.B5 clone,
from a titer of 1:1,637 to one of 1:55 (Fig. 1B). However, this
depletion was not as efficient as that for the full CAP88 gp120,
perhaps because another specificity targeting an epitope out-
side C3 but within monomeric gp120 made a minor contribu-
tion to the autologous neutralization. This was also suggested
by the significant levels of binding of the 63-88C3-depleted
plasma to CAP88 gp120 (Fig. 1C). Nevertheless, the use of a
chimeric protein where only the target of interest was present
likely increased the specificity by reducing the binding of
non-C3 antibodies. Indeed, the heterologous CAP63 gp120 did
not adsorb any neutralizing activity in the plasma from either
time point and therefore served as a suitable negative control
(Fig. 1B and D). This protein, however, very efficiently de-
pleted the CAP63 binding antibodies in this plasma, as ex-
pected (Fig. 1C and E). Little or no difference in binding to
CAP88 gp120 was observed after adsorption with CAP63
gp120-coated beads (Fig. 1C and E). This might be explained
by the presence of a large quantity of CAP88 type-specific
binding antibodies in these plasma samples that were not ad-
sorbed by CAP63 gp120, which generated a saturating signal in
the ELISA.
Epitope-specific memory-B-cell sorting. In order to isolate
the B cells that produced these anti-C3 antibodies, a differen-
tial sorting strategy using the chimeric and heterologous
gp120s labeled with different fluorochromes was designed. The
chimeric 63-88C3 gp120 was used to identify B cells that spe-
cifically recognized the C3 epitope, while the CAP63 gp120 was
used to exclude B cells expressing antibodies that bound to
regions outside the C3. Given that the anti-C3 antibody titers
in plasma peaked at 26 weeks postinfection (Fig. 1A) and were
effectively removed by the chimeric gp120, we proposed that
PBMCs collected after this time should contain memory B cells
specific for this epitope. Thus, PBMCs collected at 34 weeks
postinfection were stained with a panel of antibodies as well as
CAP63 gp120 conjugated to Pacific Blue and 63-88C3 gp120
conjugated to Alexa Fluor 647. Memory B cells (CD19,













IgD) positively stained with 63-88C3 gp120 but negative for
the heterologous CAP63 gp120 were sorted into single cells
and placed into a 96-well plate for amplification of heavy-chain
(VH) and light-chain (VL) antibody genes (Fig. 2). The fre-
quency of epitope-specific cells acquired from this sorting was
approximately 16/10,000 memory B cells. However, upon fur-
ther analysis, it was noted that a group of double-positive cells
was inadvertently included in the sorting gate. Of the 64 cells
sorted, 16 functional heavy- and light-chain pairs were identi-
fied and expressed as full-length IgG1 recombinant antibodies
in 293T cells by transient transfection using linear Ig gene
expression cassettes (15). The supernatants containing the ex-
pressed antibodies were tested for binding to the 63-88C3 and
CAP63 gp120s in a multiplex Luminex binding antibody assay.
Seven of the 16 expressed recombinant antibodies bound 63-
88C3 gp120, and 6 bound the CAP63 gp120 to various levels,
possibly due to the inclusion of the double-positive population
(Fig. 3A). The one MAb which failed to bind CAP63, 3469L,
had the highest binding to 63-88C3 gp120, suggesting that it
specifically recognized the C3 domain of CAP88. Confirmation
FIG. 1. Adsorption of autologous neutralizing activity by autologous monomeric gp120. (A) Graph adapted from Moore et al. (19) to show the
presence of the anti-C3 and anti-V1V2 neutralizing antibodies in CAP88 plasma samples collected during the course of infection. The black line
shows the response against the early CAP88 virus 88.2mo.B5, while the gray area delineates the portion attributed to anti-C3 antibodies and the
gray stripped lines delineate the portion attributed to anti-V1V2 antibodies. Plasma samples collected at 26 weeks (B and C) and 54 weeks (D and
E) postinfection were adsorbed with CAP88 and CAP63 gp120-coated beads as well as blank beads. The plasma sample collected at 26 weeks was
also adsorbed with a chimeric CAP63 gp120 grafted with the C3 region of CAP88 (63-88C3). Absorbed plasma samples were tested for
neutralization of the autologous virus 88.2mo.B5 (B and D) and for binding to all the proteins used for adsorptions (C and E). OD, optical density.













of this came from the observation that the 3469L supernatant
was the only one that neutralized the autologous virus
88.2mo.B5 significantly above background levels (Fig. 3B).
One of the other MAbs isolated, CAP88-3468L, which bound
strongly to both wild-type and chimeric proteins (Fig. 3A), was
shown on further screening to recognize the V3 loop of gp120
(unpublished data). This anti-V3 MAb, however, showed no
neutralization activity against the CAP88 virus.
Neutralization profile of CAP88-CH06 MAb. The variable
heavy- and light-chain regions of 3469L, from now referred to
as CAP88-CH06, were cloned into an IgG1-expressing vector
and produced on a large scale for further assessment of neu-
tralizing activity. In the TZM-bl pseudovirus assay, the CAP88-
CH06 MAb neutralized the early-infection clone 88.2mo.B5
very potently with an IC50 of 13 ng/ml (Fig. 4A). A similar level
of activity was noted against the autologous transmitted/
FIG. 2. Epitope-specific memory-B-cell staining. PBMCs from CAP88 at 34 weeks postinfection were stained for flow cytometric analysis and
single-cell sorting. Memory B cells were selected as lymphocytes using geometric gates and live cells using a viability marker and then as
CD3/CD14/CD16/CD235a, CD19, and surface IgD. Memory B cells positively stained with the chimeric protein 63-88C3-AF647 and negative
for CAP63-Pacific Blue (PacBlue; square gate) were sorted individually into a 96-well plate. A population of cells that stained positive for both
markers was inadvertently included in the sorted population (lower right edge of gate in the bottom panel). FSC and SSC, forward and side scatter,
respectively.













founder virus from CAP88 represented by clone 88.1mo.17,
which had a gp120 amino acid sequence identical to that of
88.2mo.B5 gp120. This MAb, however, did not neutralize eight
CAP88 viruses amplified from 6 and 12 months postinfection,
when escape from this antibody specificity had already oc-
curred (21) (Fig. 4A). Furthermore, no neutralizing activity
was recorded at 50 g/ml against a panel of 46 heterologous
viruses, which included the subtype A (n 	 6), B (n 	 12), and
C (n 	 12) tier 2 panels (27) and the neutralization-sensitive
strains MW965.26, SF162, and HxB2 (data not shown). It also
failed to neutralize any of the 12 viruses from within the
CAPRISA cohort (9) or the consensus C strain (10).
A similar pattern was observed in the PBMC neutralization
assay. The MAb CAP88-CH06, was capable of neutralizing an
infectious clone containing the envelope from the transmitted/
founder autologous virus, 88.1mo.17, but not the escaped virus,
88.6mo.10, isolated at 6 months of infection (Fig. 4B). Inter-
estingly, neutralization of the 88.1mo.17 virus was 
8 times
more potent in the PBMC assay than in the TZM-bl pseudo-
virus assay, with an IC50 of 1.7 ng/ml, although the curves were
flatter in the PBMC assay. The escaped 88.6mo.10 virus con-
tained 2 amino acid mutations (I339N and E350K) in the
alpha-2 helix of C3 which were previously shown to mediate
escape from autologous plasma (21). Here we found that the
CAP88-CH06 MAb was able to neutralize the escape virus
obtained at 6 months in which these 2 sites were backmutated
(88.6mo.10.N339I K350E), providing direct proof that this
MAb targeted the predicted C3 epitope (Fig. 4C).
The CAP88-CH06 epitope is occluded by glycans. We pre-
viously showed that escape from plasma neutralization in
CAP88 was mediated by the I339N mutation, which introduced
an N-linked glycosylation site, in combination with either an
E343K or E350K charge change in the alpha-2 helix (21).
These three residues, which are separated on a linear se-
quence, lie adjacent to one another on the solvent-exposed
side of the helix, an arrangement that likely contributed to the
formation of this epitope (highlighted in red in Fig. 5).
To further explore the role of these changes in the escape
from CAP88-CH06 neutralization, we introduced combina-
tions of these 3 escape mutations into the sensitive 88.2mo.B5
virus and measured the acquisition of neutralization resistance
(as opposed to measuring acquisition of sensitivity, as shown in
Fig. 4C). The isoleucine (I) at position 339 in the autologous
clone 88.2mo.B5 was mutated to an asparagine (N), alone or in
combination with a charge change from glutamic acid (E) to
lysine (K) at position 343 or 350. In addition, the isoleucine 339
was also changed to a glutamine (Q) to assess whether glyco-
sylation per se or just the change from a hydrophobic to a
hydrophilic residue at this position could mediate escape. The
I339N substitution mediated partial resistance, with a 7-fold
increase in IC50 from 13.2 to 102.9 ng/ml (Fig. 6A). However,
the I339Q substitution had a minimal effect on neutralization
resistance, emphasizing the contribution of the N-linked glycan
at this position in conferring escape from this antibody. The
addition of either E343K or E350K in combination with the
N339 glycan resulted in complete resistance to neutralization
by the CAP88-CH06 MAb, even at 10 g/ml. Interestingly,
while the E343K mutant showed a 43-fold increase in IC50 but
remained neutralization sensitive, the introduction of the
E350K mutation on its own resulted in a completely resistant
variant. However, no naturally occurring sequences with only
the E350K mutation were found among the 7 clones that were
analyzed (21). This suggested that resistance to this MAb was
mediated by the combined effects of both the charge change at
position 343 or 350 and the N-linked glycan at position 339.
To further explore the role of N-linked glycosylation
in CAP88-CH06 MAb neutralization, the sensitive virus
88.2mo.B5 was produced in 293T cells in the presence of ki-
funensine or in cells that lacked N-acetylglucosamine trans-
ferase I (GnTI-deficient 293S). Kifunensine inhibits the en-
FIG. 3. Binding and neutralization of the isolated antibodies. The seven isolated VH and VL pairs were transiently transfected in 293T cells.
Their supernatants were screened for binding to CAP63 and 63-88C3 gp120s by Luminex (A) and tested for neutralization of autologous virus
88.2mo.B5 isolated during acute infection in the TZM-bl assay (B). High background levels in the neutralization screening assay, as seen in the
mock transfections, may be due to the transfection reagent or other toxins in these concentrated supernatants.













zyme mannosidase I, which is responsible for trimming the
Man9 precursor into Man5. This is the preliminary step in the
synthesis of hybrid and complex glycans, and treatment with
kifunensine results in a virus rich in large high-mannose Man9
glycans (2). Conversely, viruses grown in GnTI-deficient 293S
cells mainly carry Man5 glycans, due to the failure of these cells
to produce hybrid or complex glycans. It has been proposed
that viruses produced in 293T cells express Man5-rich glycans
on their envelope glycoproteins and therefore do not substan-
tiality differ from viruses grown in GnTI-deficient 293S cells
(4). The virus produced in the presence of kifunensine was
resistant to neutralization by CAP88-CH06, while the virus
produced in GnTI-deficient 293S cells was more sensitive than
the control virus grown in 293T without kifunensine (Fig. 6B).
Altogether, these data suggested that the exposure of the
CAP88-CH06 epitope is affected by the glycan moieties, which
may have been exploited by the virus to escape from this
antibody response.
Escape did not result in loss of binding to recombinant
gp120. Having found mutations in the C3 region that totally
abrogated neutralization by CAP88-CH06, we investigated
whether these escape mutations resulted in the loss of binding
to gp120. Monomeric gp120 proteins from the clone
88.2mo.B5 and the escape mutant 88.2mo.B5.I339N E343K
were produced in 293T cells and tested for binding to the MAb
CAP88-CH06. CAP63 gp120 was used as a negative control.
The anti-V3 MAb CAP88-3468L, which was used as a positive
control, bound all three proteins equally well, as expected (Fig.
7B). The autologous neutralizing antibody CAP88-CH06 did
not bind the CAP63 gp120, confirming the isolate-specific na-
ture of this MAb (Fig. 7A). However, CAP88-CH06 bound
both CAP88 gp120s, including the one containing the two
escape mutations, albeit at slightly lower levels. This indicated
that neutralization escape does not necessarily preclude bind-
ing to recombinant gp120. Given this dichotomy between neu-
tralization and binding, we captured gp120 from lysed pseudo-
virus supernatants grown in 293T cells and tested them for
binding to the MAbs. Interestingly, the MAb CAP88-CH06
was not able to bind the gp120 from the escape mutant or the
heterologous gp120, while it efficiently bound the gp120 de-
rived from the enrollment virus (Fig. 7C), consistent with the
neutralization profile and in contrast to the binding to recom-
binant gp120. The anti-V3 MAb was able to bind all three
proteins similarly, confirming that the differences in CAP88-
CH06 binding were not the result of variations in the amount
of captured gp120.
FIG. 4. Neutralization escape from CAP88-CH06 MAb. Purified
CAP88-CH06 MAb was tested for neutralization of autologous CAP88
clones isolated at 1, 2, 6, and 12 months postinfection in the TZM-bl
assay (A), infectious molecular clones of viruses from 1 and 6 months
in a PBMC neutralization assay (B), and a clone obtained at 6 months
in which the N339I and K350E changes were introduced (C). MFI,
mean fluorescence index.
FIG. 5. Location within the alpha-2 helix of the amino acid residues
involved in neutralization escape. The CAP88.2mo.B5 gp120 amino
acid sequence was modeled using coordinates from the CAP210 gp120
structure in complex with secretory CD4 and 21c Fab (Protein Data
Bank accession no. 3LQA) and the Modeler (version 9.8) program. A
ribbon diagram of the alpha-2 helix was used to display the location of
the 3 amino acids (in red) in the alpha-2 helix of CAP88 that mediated
escape from the CAP88-CH06 MAb. Sequences of this region from 2
representative clones at 6 months compared to the sequence of the
clone at 2 months showed that the addition of a glycan at position 339
was common, while charge changes at position 343 or 350 were mu-
tually exclusive, occurring on equal numbers of separate genomes (21).
The figure was generated with the PyMOL program (DeLano Scien-
tific LLC, South San Francisco, CA [http://www.pymol.org]).













Sequence analysis of variable region of the MAb CAP88-
CH06. The VH and VL sequences of CAP88-CH06 were ana-
lyzed using the SoDA (31) and JoinSolver (28) programs. The
heavy chain was shown to belong to the IgA1 subclass, and the
maximum-probability inferred gene recombinations were
VH4
39*01, DH3
3*01, and JH4*02 genes for the heavy
chain and V3
21*03 and J2*01 genes for the lambda chain.
The antibody sequences were compared to the closest reported
germ line sequence and indicated that CAP88-CH06 had 21
mutations (5.9%) in the heavy-chain gene with insertions of 6
nucleotides in the CDR2 and 8 mutations (3.3%) in the light-
chain gene. A high ratio of synonymous to nonsynonymous
mutations was observed, suggesting that a certain level of af-
finity maturation from the germ line sequence took place (Fig.
8). However, it is not known if all these mutations were re-
quired to achieve the binding threshold required for neutral-
ization.
DISCUSSION
We used epitope-specific sorting of memory B cells to isolate
a monoclonal antibody that reflects the primary neutralizing
response in an HIV-1 subtype C-infected individual. Mapping
of this antibody specificity and its epitope was previously done
using autologous plasma, and this information was used to
design a suitable antigen to sort relevant B cells from stored
PBMCs. This MAb, called CAP88-CH06, defined an epitope
in the alpha-2 helix of the C3 region of the outer domain of the
HIV-1 envelope and potently neutralized early autologous vi-
ruses. Furthermore, the isolation of this antibody allowed the
precise definition of the neutralization escape mechanism that
occurred in this HIV-1 subtype C-infected individual within
the first 6 months of infection.
The use of a highly specific antigen combined with identifi-
cation and sorting of memory B cells is an extremely powerful
way to isolate antibodies of interest. Indeed, a similar strategy
was used to isolate the MAbs VRC01, VRC02, and VRC03,
where a mutated and unmutated resurfaced gp120 was used to
specifically identify the B cells of interest (34). Here, we de-
signed a chimeric gp120 that contained only a small fragment
encompassing the target sequence to increase the specificity of
sorting. Since gp120 is a complex antigen which is the target of
numerous cross-binding antibodies, the heterologous gp120
employed as the chimera backbone was utilized to essentially
soak up the irrelevant antibodies, as these stained with both
fluorochromes. The B cells binding to the chimeric protein
were therefore enriched for CAP88-C3 type-specific antibod-
ies. Indeed, close analysis of the flow cytometric plot showed
distinct populations of double-positive cells and more diffuse
labeling of single-positive cells (Fig. 2). The anti-V3 MAb that
was isolated in addition to the anti-C3 MAb during this pro-
cedure likely came from the single-positive-cell gate that
slightly overlapped the population of double-positive cells. The
proportion of single sorted cells was 0.16% (including the
overlap) of memory B cells. The ability of cell sorting to iden-
tify 1 in 10,000 cells in combination with the capacity to amplify
heavy- and light-chain genes from single cells makes this a
highly desirable approach to fishing out MAbs of interest.
While the use of a differential sorting strategy is probably less
specific than sorting double-positive cells, as we did previously
using a peptide tetramer to isolate an MPER-specific MAb
(22), it does allow sorting of B cells where the target is part of
a complex structural protein, as opposed to a peptide. How-
ever, knowledge of whether or not the antibody of interest
binds the antigen and depletes the neutralizing activity is cru-
cial before embarking on this approach. Furthermore, this
method could be adapted to isolate broadly neutralizing anti-
bodies where the epitopes on gp120 have been identified. An-
tibodies which recognize quaternary epitopes, present only on
trimeric envelopes, such as PG9/16 (32) or even the anti-V1V2
antibody, which appears in CAP88 as the second arising spec-
ificity (21), would not be amenable to this approach at this
stage.
The CAP88-CH06 MAb substantially recapitulated the ac-
tivity seen in plasma, suggesting that a single antibody was
responsible for the primary neutralizing response in this indi-
vidual. However, since we isolated only a single antibody, we
cannot be certain that other antibodies with the same specific-
ity that either were somatic variants or used different germ line
genes were also involved. Indeed, there appears to be signifi-
cant redundancy in the immune system, as others have shown
that both these scenarios have occurred (17, 24, 34). The
CAP88-CH06 MAb was highly type specific and failed to neu-
tralize any viruses other than the earliest autologous viral
clones. It did, however, neutralize both in a cell line and in
primary PBMCs, although it did so more potently in the latter
assay, which may be related to glycosylation patterns and/or
coreceptor density. Comparison of the CAP88-CH06 VH and
FIG. 6. Effect of N-linked glycosylation on neutralization. (A) The
I339 residue in the neutralization-sensitive clone 2mo.B5 was replaced
by a glutamine (Q) or asparagine (N). Charge change E343K or E350K
was introduced with or without the N339 glycan. All mutants were
tested for neutralization by the CAP88-CH06 MAb starting at 10
g/ml. (B) The CAP88 clone 2mo.B5 was grown in the presence of 100
M kifunensine or in GnTI-deficient 293S cells to determine the effect
of the glycans on the neutralization by CAP88-CH06 MAb.













VL sequences to the closest germ line showed them to be 5.9%
and 3.3% divergent, respectively. This is considerably lower
than the divergences for existing broadly cross-neutralizing
MAbs, which range from a 12% mutation rate in the VH genes
for 4E10 (11) to one of 31% for VRC01 (34). Thus, high
neutralization potency was achieved without necessitating a
large number of somatic mutations, which may explain in part
why they arise much earlier than the highly mutated broadly
cross-neutralizing antibodies. However, more early autologous
neutralizing MAbs from other individuals need to be isolated
and characterized to determine if this is a general feature that
explains the immunodominance of such type-specific epitopes.
The observation that kifunensine treatment resulted in a
virus resistant to neutralization by the MAb CAP88-CH06,
while virus grown in GnTI-deficient 293S cells was more sen-
sitive, suggested that the exposure of this epitope was depen-
dent on the size of the “glycan fence,” as first described by
Binley et al (2). Indeed, escape from this MAb occurred rap-
idly and was mediated by the insertion of a glycosylation site,
in addition to a charge change at position 343 or 350 in the
alpha-2 helix. Changes in glycosylation have been shown to
mediate neutralization escape (33). In this case, the N339
glycan only partially occluded the epitope, and therefore, a
charge change, possibly within the binding site, was required
for complete escape. It is unclear why HIV uses more than one
pathway to escape pressure from such a monospecific neutral-
izing response. The K343E and K350E mutations were equally
represented in the sequences of virus obtained at 6 and 12
months (21), suggesting that these changes were similarly fa-
vored and presumably had comparable or perhaps no fitness
consequences. It is interesting that no sequences contained
only the K350E change in the absence of the glycan at position
339, given that this artificially constructed virus was highly
resistant to CAP88-CH06 in vitro. Perhaps the N339 glycan
may have been performing additional functions, such as pro-
viding a compensatory mutation or mediating escape from
other antibodies in the CAP88 plasma.
We observed here that mutations that rendered the virus
resistant to neutralization by CAP88-CH06 MAb did not to-
tally abrogate the binding of this antibody to recombinant
gp120 but effectively precluded the recognition of pseudovirus-
derived gp120. Thus, the effect of the escape mutations was
apparent only in the envelope produced by the virus and not on
the recombinant protein. A recent study suggested that recom-
binant gp120 is rich in complex-type glycans, in contrast to
virion-associated gp120, which contains an oligomannose pro-
file (Man5-9GlcNAc2) with less than 2% complex glycans (4).
Given that escape from this antibody depends largely on a
FIG. 7. CAP88 MAb binding to gp120 made from autologous and mutant viruses. Recombinant gp120s produced in 293T cells from wild-type
88.2mo.B5 and escape mutant 88.2mo.B5 containing two amino acid changes (I339, E343K) were tested in an ELISA for binding to anti-C3
CAP88-CH06 (A) and anti-V3 CAP88-3468L (B) MAbs. CAP63 gp120 was used as a control. Virion-associated gp120s were captured from lysed
pseudovirus stocks produced in 293T cells via the D7324 antibody and tested for binding to anti-C3 CAP88-CH06 (C) and anti-V3 CAP88-3468L
(D) MAbs.













mannose-rich glycan, this difference may explain the paradox
between these two binding experiments. This is an important
observation that should be kept in mind when using recombi-
nant gp120 either as an immunogen or a reagent.
We have previously shown that the C3 region, in particular,
the alpha-2 helix, is commonly recognized by early autologous
neutralizing antibodies in subtype C infections (20). Here we
have isolated an antibody that represents this early specificity
and that potently neutralized the autologous virus. However,
escape required only two amino acid changes, attesting to the
daunting plasticity faced by the immune system in dealing with
HIV infection. Our findings provide clues as to why the early
neutralizing responses are type specific. First, they recognize a
region which is highly exposed and variable among subtype C
viruses (6) as well as structurally different from subtype B
envelopes (7). Second, it is possible that most antibodies
against this region, like CAP88-CH06, are strongly dependent
on side chain interactions for recognition and are easy to
escape. The alpha-2 helix is only 18 amino acids in length and
has structural restrictions, such as the need to maintain am-
phipathicity and a solvent-exposed face. The fact that this
region is under such enormous pressure early in HIV infection
suggests that it is highly immunogenic and favored by the
immune system and therefore may represent an important
target in vaccine design. However, finding structurally con-
served motifs in this region that can be recognized by more
broadly cross-neutralizing antibodies remains a significant
challenge.
In summary, we successfully employed differential gp120
sorting to isolate an antigen-specific memory B cell encoding a
MAb that targets a specific epitope in the envelope glycopro-
tein. This demonstrated that even in the absence of detailed
FIG. 8. Sequence analyses of the VH and VL genes of the CAP88-CH06 MAb. The variable region sequences of CAP88-CH06 were compared
to the closest germ line sequence for both the heavy-chain (HC) (A) and light-chain (LC) (B) genes. Light gray and black highlights, nonsyn-
onymous and synonymous changes, respectively; dark gray highlighting, a 6-nucleotide insertion in the heavy-chain complementarity-determining
region 2 (CDR2). Framework regions (FR) 1, 2, and 3 and complementarity-determining regions (CDR) 1, 2, and 3 are indicated.













structural knowledge of the target epitope, chimeric autolo-
gous proteins can be used to identify the B cells of interest. The
isolated MAb CAP88-CH06 represented the primary neutral-
izing response and contained a low level of somatic mutations
in their variable regions. Furthermore, it allowed the study of
the neutralization escape from the first autologous antibody
response in this HIV-1 subtype C-infected individual.
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